Last update 25 Jun 2025

Etoricoxib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
5-chloro-2-(6-methylpyridin-3-yl)-3-(4-(methylsulfonyl)phenyl)pyridine, 5-Chloro-3-(4-methanesulfonyl-phenyl)-6'-methyl-[2,3']bipyridinyl, 5-chloro-6'-methyl-3-(p-(methylsulfonyl)phenyl)-2,3'-bipyridine
+ [14]
Target
Action
inhibitors
Mechanism
COX-2 inhibitors(Cyclooxygenase-2 inhibitors)
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
Australia (11 Oct 2002),
RegulationPriority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC18H15ClN2O2S
InChIKeyMNJVRJDLRVPLFE-UHFFFAOYSA-N
CAS Registry202409-33-4

External Link

KEGGWikiATCDrug Bank
D03710Etoricoxib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Rheumatoid Arthritis
China
31 Dec 2008
Arthritis, Gouty
China
21 May 2007
Dysmenorrhea
China
21 May 2007
Acute Pain
Australia
11 Oct 2002
Osteoarthritis
Australia
11 Oct 2002
Primary gout
Australia
11 Oct 2002
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Osteoarthritis, HipPhase 3
Germany
01 Feb 2011
Ankylosing SpondylitisPhase 3-27 Sep 2010
BursitisPhase 3
Peru
01 Nov 2009
Soft Tissue InjuriesPhase 3
Peru
01 Nov 2009
Soft tissue rheumatismPhase 3
Peru
01 Nov 2009
TenosynovitisPhase 3
Peru
01 Nov 2009
HemorrhagePhase 3
Germany
01 Oct 2008
Postoperative HemorrhagePhase 3
Germany
01 Oct 2008
Postoperative Nausea and VomitingPhase 3
Germany
01 Oct 2008
Pain, PostoperativePhase 3
Germany
01 Feb 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
28
Exib
(Test (Exib))
vqjgvgyxzc(wrwkncguoo) = uicqqfvyci qaafhbvexp (doyfqufqzp, 577.431)
-
29 Nov 2024
(Reference (Arcoxia®))
vqjgvgyxzc(wrwkncguoo) = aoneliwcsa qaafhbvexp (doyfqufqzp, 602.446)
Phase 2
144
Prophylactic Etoricoxib
vacjoyzfoj(yuwtdkgtrl) = rkzjyhdoky jadhcwhqhh (dcxvejospd )
Positive
16 Jun 2022
(No Prophylactic Treatment)
vacjoyzfoj(yuwtdkgtrl) = fpcasywajl jadhcwhqhh (dcxvejospd )
Not Applicable
21
jrulwxkckb(fpkykpktef) = in 10% wsipmtvdwx (xflsdzsqiw )
-
01 Jun 2022
Not Applicable
790
kuezidwimy(melvnnioyz) = mainly dyspepsia and arterial hypertension ztptfpxmlp (uddkbsurug )
Positive
01 Jun 2022
Phase 3
776
Matching Placebo for Ibuprofen+Oxycodone+Morphine+Etoricoxib 90 mg
(Etoricoxib 90 mg)
avtoxzysxc(qfcmnguvem) = mkqszembpn mkyvoxxvjp (iyavatkihn, cahrxmysbl - hkvynajenh)
-
07 Apr 2020
Matching Placebo for Ibuprofen+Oxycodone+Morphine+Etoricoxib 120 mg
(Etoricoxib 120 mg)
avtoxzysxc(qfcmnguvem) = mwdudjgfix mkyvoxxvjp (iyavatkihn, wwdzhqlusv - xdcyvpxbyg)
Phase 4
80
adphcxvltk(ptxpxliqfs) = WOMAC pain sub-score improving by 30.7% whilst Placebo group values worsened. bcmjngimae (kshznrwnev )
Positive
01 Nov 2017
Placebo
Phase 3
1,015
ernugodhrg(ijwjvloskl) = reduction non-inferior wijqvfnxrv (stnriqiszx )
Non-inferior
13 Oct 2016
Not Applicable
40
zjoaqqvhsj(zjixjxiaxj) = owajqkswvq awmzuauhqa (zfanhtohzp, 1 - 8)
-
10 Jun 2015
Phase 3
58
iqlrnvtoih = urhqhevbjq hhdvakfmfu (asxrysaeau, iqdwlalsmd - rmlwyhiqhi)
-
10 Jun 2015
Phase 3
239
pfzhkadbmd(vindfafnas) = mirybpvsdl fjusumzxaa (fviqacivad, ( - 5.37, 2.10))
Positive
01 Dec 2014
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free